Sign up to save your podcasts
Or
Share Exploring the role of targeted radiopharmaceutical treatment in NETs
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Exploring the role of targeted radiopharmaceutical treatment in NETs
Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients.
We cover essential topics such as:
• The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning
• Second-line standard use of PRRT and emerging data for first-line therapy
• Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression
• Balancing sequencing strategies in well-differentiated and higher-grade tumors
• The critical role of multidisciplinary tumor boards in NET management
• Future directions including PRRT retreatment and ongoing clinical trials
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology!
#NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to the Oncology Brothers podcast! In this episode, we dive into the evolving landscape of neuroendocrine tumors (NETs) with guests Dr. Heloisa Soares, a medical oncologist, and Prof. Ken Herrmann, a nuclear medicine specialist. Together, we explored the role of Peptide Receptor Radionuclide Therapy (PRRT), imaging breakthroughs, and treatment sequencing to optimize outcomes for NET patients.
We cover essential topics such as:
• The role of Gallium-68 and Copper-64 DOTATATE PET imaging in diagnosis and planning
• Second-line standard use of PRRT and emerging data for first-line therapy
• Toxicities of PRRT—nausea, kidney toxicity, and bone marrow suppression
• Balancing sequencing strategies in well-differentiated and higher-grade tumors
• The critical role of multidisciplinary tumor boards in NET management
• Future directions including PRRT retreatment and ongoing clinical trials
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and tune in for more discussions on challenging cases, treatment algorithms, and expert insights in the field of oncology!
#NeuroendocrineTumors #NETs #PRRT #OncologyBrothers #CancerTreatment #NuclearMedicine
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
324 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
295 Listeners
White Coat Investor Podcast
2,439 Listeners
The Curbsiders Internal Medicine Podcast
3,358 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
204 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
22 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
59 Listeners
Two Onc Docs
193 Listeners